<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02386397</url>
  </required_header>
  <id_info>
    <org_study_id>ICM2013/09</org_study_id>
    <nct_id>NCT02386397</nct_id>
  </id_info>
  <brief_title>Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer</brief_title>
  <acronym>BREGO</acronym>
  <official_title>Activity of Regorafenib in Combination With Modified Gemcitabine - Oxaliplatin Chemotherapy (mGEMOX) in Patients With Advanced Biliary Tract Cancer (BTC): A Phase Ib-II Trial (BREGO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to determine the Regorafenib Dose (RD) for the phase II trial of Regorafenib&#xD;
      administered in combination with mGEMOX in patients with advanced biliary tract cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Regorafenib (BAY 73-4506) was assessed in metastatic colorectal cancer in the phase III&#xD;
      randomized CORRECT trial. 760 metastatic colorectal cancer patients were recruited after the&#xD;
      failure of all standard therapies.&#xD;
&#xD;
      Given the promising efficacy and favorable tolerability profile of mGEMOX and the potential&#xD;
      benefits of targeting the VEGF and Ras/Raf pathway, we propose to assess the combination of&#xD;
      Regorafenib with mGEMOX in advanced digestive cancer.&#xD;
&#xD;
      This study is to determine the Regorafenib Dose (RD) for the phase II trial of Regorafenib&#xD;
      administered in combination with mGEMOX in patients with advanced biliary tract cancer.&#xD;
&#xD;
      The phase I study of Regorafenib in advanced colorectal cancer showed a pronounced&#xD;
      interindividual variability of drug exposition. Furthermore, the CORRECT study shows a large&#xD;
      pharmacological variability of plasma concentration for Regorafenib and its metabolites. In&#xD;
      this study, we propose to explore the pharmacological variability and his potential&#xD;
      heritability by the therapeutic drug monitoring of Regorafenib. The objective is to&#xD;
      understand and to control the pharmacological variability of Regorafenib and finally to&#xD;
      predict the therapeutic response or the toxicity, especially in a population of patients with&#xD;
      biliary tract cancer.&#xD;
&#xD;
      In addition, we will complete this study by exploring the gene variants of drug metabolism.&#xD;
      The genes are POR (P450 OxidoReductase,) NR1I2 (Nuclear Receptor subfamily 1, group I, member&#xD;
      2) and a part of the regulatory sequences of CYP3A4.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Limiting toxicity</measure>
    <time_frame>up to 5 years</time_frame>
    <description>To assess Limiting Toxicities during and within 6 weeks (2 cycles) after the beginning of the treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Digestive Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regorafenib: X mg/d, PO, from day 1 to day 14; day 15 to day 20: off-treatment mGEMOX: infusion on days 1 and 8&#xD;
Gemcitabine 900 mg/m² IV in 30 minutes&#xD;
Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>mGEMOX: infusion on days 1 and 8&#xD;
Gemcitabine 900 mg/m² IV in 30 minutes&#xD;
Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib</intervention_name>
    <description>Regorafenib: X mg/d, PO, from day 1 to day 14; day 15 to day 20: off-treatment</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Gemcitabin</other_name>
    <other_name>Oxaliplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GEMOX</intervention_name>
    <description>mGEMOX: infusion on days 1 and 8: Gemcitabine 900 mg/m² IV in 30 minutes Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine</description>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Gemcitabine</other_name>
    <other_name>Oxaliplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adenocarcinoma of the biliary tract&#xD;
&#xD;
          -  Metastatic disease with no curative surgery option or metastatic recurrence after&#xD;
             resection.&#xD;
&#xD;
          -  Only for phase II: At least one measurable lesion in a non-irradiated area according&#xD;
             to Response Evaluation Criteria in Solid Tumors&#xD;
&#xD;
          -  No biliary obstruction.&#xD;
&#xD;
          -  Age between 18 and 75 years.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          -  Life expectancy higher than 3 months.&#xD;
&#xD;
          -  No prior chemotherapy for advanced disease. Previous adjuvant chemotherapy including&#xD;
             Gemcitabine and/or platinum based is allowed if completed at least 6 months previously&#xD;
             and relapsing after completion of the last dose.&#xD;
&#xD;
          -  Total bilirubin ≤ 2.5 times the upper limit of the normal range. Patients with&#xD;
             jaundice or evidence of bile duct obstruction, in whom the biliary tree can be&#xD;
             decompressed by endoscopic or percutaneous endoprothesis (at least 15 days before&#xD;
             inclusion) with subsequent reduction in total bilirubin ≤ 3 ULN, will be eligible for&#xD;
             the study.&#xD;
&#xD;
          -  Aminotransferases (AST, ALT) ≤ 2.5 ULN (≤ 5 ULN in case of diffuse hepatic&#xD;
             involvement), INR &lt; 1.5 (following vitamin K1 injection in patients with current or&#xD;
             recent history of jaundice or bile duct obstruction), serum creatinine clearance&#xD;
             calculated &gt; 50 mL/min/1.73m² according to the Modification of Diet in Renal Disease&#xD;
             (MDRD) formula, neutrophils ≥ 1.5.109/L, platelets ≥ 100.109/L, hemoglobin ≥ 9 g/dL&#xD;
             (red blood cell transfusion is allowed if needed).&#xD;
&#xD;
          -  Signed informed consent obtained before any study specific procedures.&#xD;
&#xD;
          -  Patients must be affiliated to a Social Security System.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known central nervous system metastases.&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Contraindication or history of allergic reaction to one of the treatment components.&#xD;
&#xD;
          -  Previous irradiation (external radiotherapy or brachytherapy) within 30 days prior to&#xD;
             study treatment.&#xD;
&#xD;
          -  Major surgery within 30 days prior to study treatment.&#xD;
&#xD;
          -  Participation in another clinical trial within 30 days prior to study treatment.&#xD;
&#xD;
          -  Concomitant systemic immunotherapy, chemotherapy, antitumor hormone therapy, targeted&#xD;
             therapy or any experimental therapy.&#xD;
&#xD;
          -  Active uncontrolled infection, peripheral neuropathy grade ≥ 2, acute or subacute&#xD;
             bowel obstruction, history of inflammatory bowel disease, interstitial pneumonitis,&#xD;
             respiratory failure, renal failure, dysphagia or any malabsorption condition.&#xD;
&#xD;
          -  Symptomatic coronary heart disease or myocardial infarction in the past 6 months,&#xD;
             congestive heart failure (NYHA class II), prior cerebrovascular accident.&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic blood pressure (BP) &gt; 150 mmHg or diastolic&#xD;
             pressure &gt; 90 mmHg despite optimal medical management).&#xD;
&#xD;
          -  Proteinuria of National Cancer Institute Common Terminology Criteria for Adverse&#xD;
             Events (NCI-CTCAE) ≥ grade 2 (i.e. urinary protein ≥ 1.0 g/24 hrs).&#xD;
&#xD;
          -  Patients with current or anticipated need for strong Cytochrome P450 3A4 (CYP3A4)&#xD;
             inhibitors or inducers.&#xD;
&#xD;
          -  Pregnancy (or positive β-HCG dosage at inclusion), breast-feeding, or lack of&#xD;
             effective contraception in male or female patients of reproductive potential.&#xD;
&#xD;
          -  Other malignancies either currently active or in the last 5 years, except adequately&#xD;
             treated in situ carcinoma of the cervix and basal or squamous cell skin carcinoma.&#xD;
&#xD;
          -  Legal incapacity or physical, psychological or mental status interfering with the&#xD;
             patient's ability to sign the informed consent or to terminate the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DOMERGUE Jacques</last_name>
    <role>Study Director</role>
    <affiliation>Institut régional du Cancer - Val d'Aurelle</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>March 2, 2015</study_first_submitted>
  <study_first_submitted_qc>March 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2015</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

